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Abstract
Introduction The aim of this study was to evaluate the performance of five general severity-of-illness
scores (Acute Physiology and Chronic Health Evaluation II and III-J, the Simplified Acute Physiology
Score II, and the Mortality Probability Models at admission and at 24 hours of intensive care unit [ICU]
stay), and to validate a specific score – the ICU Cancer Mortality Model (CMM) – in cancer patients
requiring admission to the ICU.
Methods A prospective observational cohort study was performed in an oncological medical/surgical
ICU in a Brazilian cancer centre. Data were collected over the first 24 hours of ICU stay. Discrimination
was assessed by area under the receiver operating characteristic curves and calibration was done
using Hosmer–Lemeshow goodness-of-fit H-tests.
Results A total of 1257 consecutive patients were included over a 39-month period, and 715 (56.9%)
were scheduled surgical patients. The observed hospital mortality was 28.6%. Two performance
analyses were carried out: in the first analysis all patients were studied; and in the second, scheduled
surgical patients were excluded in order to better compare CMM and general prognostic scores. The
results of the two analyses were similar. Discrimination was good for all of the six studied models and
best for Simplified Acute Physiology Score II and Acute Physiology and Chronic Health Evaluation III-
J. However, calibration was uniformly insufficient (P  < 0.001). General scores significantly
underestimated mortality (in comparison with the observed mortality); this was in contrast to the CMM,
which tended to overestimate mortality.
Conclusion None of the model scores accurately predicted outcome in the present group of critically
ill cancer patients. In addition, there was no advantage of CMM over the other general models.
Keywords: cancer, mortality, outcome, severity-of-illness scores
Introduction
Advances in oncological and supportive care have improved
survival rates in cancer patients to the point that many of them
can now be cured or have their disease controlled. However,
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such advances have often been achieved through aggressive
therapies and support, at high expense [1]. Some of these
patients require admission to the intensive care unit (ICU) for
acute concurrent illness, postoperative care, or complications
of their cancer or its therapy [2]. In general hospitals, intensiv-
ists frequently consider these patients as having a poor prog-
nosis and tend to oppose their admission to the ICU [3].
Recent studies [4,5] have indicated that this reluctance to
offer ICU care to cancer patients with severe illness is unjusti-
fied, and is usually based on inequitable parameters in com-
parison with other severe and chronic diseases that share a
similarly poor prognosis [6,7]. Hence, efforts have been made
to identify parameters that are associated with worse progno-
sis and to improve allocation of ICU resources [4,5,8-11].
Prognostic scores have been used to predict outcome in
patients admitted to ICUs. Although none of these models
should be used to predict individual outcomes, they can assist
physicians in discussions of prognosis and in clinical decision
making to improve allocation of resources in intensive care
[12]. Stratification of patients for clinical research and assess-
ment of quality of intensive care are other potential applica-
tions [12-14].
However, the performance of a prognostic score must be val-
idated before it may be used in an ICU, where there is a spe-
cific mix of patients such as cancer patients. Few studies have
addressed adequately the performance (calibration and dis-
crimination properties) of prognostic scores in cancer patients
[4,9,15-17]. Some years ago a specific model with which to
predict outcome among critically ill cancer patients – the Can-
cer Mortality Model (CMM) – was developed by Groeger and
coworkers [9]. To the best of our knowledge, only one external
validation for the CMM has been conducted recently [17], and
few studies have compared different scores in cancer patients
[4,16,17]. The present study evaluated the performance of five
general prognostic models and validated the CMM in predict-




The study was conducted from May 2000 to July 2003 at the
Instituto Nacional de Câncer, a public tertiary hospital for refer-
ral of cancer patients in Rio de Janeiro, Brazil. Its ICU is a 10-
bed medical/surgical unit exclusively for oncological patients,
with full-time medical and nurse directors, and medical, physi-
otherapy and nursing staff who are qualified in intensive care;
facilities such as haemodynamic monitoring, microprocessor-
controlled mechanical ventilation and dialysis are available and
can be offered for each bed. At least two senior intensivists
and one junior intensivist are on duty 24 hours a day. In each
shift (two per day), at least two postgraduate and four under-
graduate nurses work regularly in the ICU. Most of the post-
graduate nurses have a special diploma in oncology and/or
intensive care, and take part in regular training of oncology and
intensive care nurses. The nurse/patient ratio ranges from 1.2
to 1.7. Routine clinical rounds, including medical, nurse and
physiotherapy staff, and meetings with oncologists, are done
each day in the ICU. Approximately 600 patients are admitted
each year to the ICU. The ICU uses a patient data manage-
ment system, which allows automatic capture and registration
of physiological data.
The decision regarding whether a patient should be admitted
to the ICU is made jointly by the senior intensivist and the
oncologist who is responsible for the patient's care. To be
admitted to the ICU, patients should be considered to have a
chance of being cured or having their cancer controlled. The
ICU medical staff makes decisions regarding discharge during
daily clinical rounds. Patients are always discharged to wards.
End-of-life care is offered in the ICU when a patient does not
recover from their acute illness despite ICU care. Occasion-
ally, patients (with a diagnosis of cancer) may be admitted
because of life-threatening illness identified during assess-
ment of the extent of their cancer and/or consideration of the
therapeutic options. This assessment is conducted as soon as
is possible, and end-of-life care is started if specific treatments
aimed at cancer cure or control can no longer be justified.
All consecutive patients with a definite diagnosis of cancer
(pathologically proven) admitted to the ICU because of severe
illness were included in the present study. In those patients
with multiple hospital admissions, the most recent was consid-
ered. For patients readmitted to the ICU during the same hos-
pital stay, only the first ICU admission was considered.
Patients younger than 18 years (n = 284), those with burn inju-
ries (n = 0), those with an ICU stay of less than 6 hours (n =
29) and those with definite diagnosis of acute coronary syn-
drome or in whom such a disorder could not be ruled out were
excluded (n = 15). Patients who had been considered cured
of their cancer for more than 5 years (n = 20) and those with
noncancer disease (n = 36) were also excluded. Bone marrow
transplant (BMT) patients are treated at a separate unit, even
in case of life-threatening complications; therefore, BMT
patients were not studied. The study was approved by the
institutional review board, which waived the need for informed
consent because the study did not interfere with clinical deci-
sions regarding patient care.
Measurements
At admission and over the first 24 hours of ICU stay, various
demographical, clinical and laboratory variables were
assessed. In the calculation of scores, the most disturbed val-
ues were assigned for vital signs and laboratory data. For
sedated patients, Glasgow Coma Scale score before seda-
tion was used [18]. Zero points or normal values were inserted
where data were missing [19]. There were no missing varia-
bles for physiological data. Among laboratory variables, normal
values were inserted for albumin in 623 (49.6%), prothrombinAvailable online http://ccforum.com/content/8/4/R194
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time in 274 (21.8%) and bilirubin in 676 (53.8%) patients. No
patient with jaundice on physical examination lacked serum
bilirubin measurements. Severe chronic comorbidities were
considered as defined in the assessment of each scoring sys-
tem. Patients were classified, based on reason for ICU admis-
sion, into medical, scheduled surgical and emergency surgical
groups. We also recorded the underlying malignancy (solid
tumour versus haematological malignancy), disease status
(newly diagnosed/controlled versus recurrence/progression;
locoregional versus metastatic), treatments over the 6 months
before ICU admission (chemotherapy, radiation therapy and
surgery, excluding biopsies and catheter insertions) and East-
ern Cooperative Oncology Group performance status [20]
during the week before hospital admission. Neutropenia was
defined as a neutrophil count of below 1000/mm3. The
Sequential Organ Failure Assessment score was used to
assess acute organ dysfunctions/failures [21].
The following general prognostic scores were measured: the
Simplified Acute Physiology Score (SAPS) II [22], the Mortal-
ity Probability Models at admission (MPM II0) and at 24 hours
(MPM II24) [23], and Acute Physiology and Chronic Health
Evaluation (APACHE®; a registered trademark of Cerner Cor-
poration, Kansas, MO, USA) versions II and III-J [19,24]. Each
model was applied as described in their original reports. The
mortality equations of the APACHE III-J have recently become
available for use worldwide. The CMM [9] is a cancer specific,
multivariable, logistic regression model that was specifically
designed to predict the probability of hospital death in patients
at admission to the ICU. Briefly, it comprises 16 easily evalua-
ble clinical variables: cardiac arrest before admission, endotra-
cheal intubation, intracranial mass effect, allogeneic BMT,
cancer recurrence/progression, performance status, respira-
tory rate, systolic blood pressure, arterial oxygen tension/frac-
tional inspired oxygen ratio, Glascow Coma Scale score,
platelet count, prothrombin time, serum albumin, bilirubin,
blood urea nitrogen, and number of hospital days before ICU
admission (lead time). Hospital mortality was the main end-
point of interest.
Data management and statistical analysis
Data were entered into a computer database by a single
author (MS). In order to ensure data consistency, another sin-
gle author (JRR) cross-checked every variable entered, and a
final recheck procedure was conducted for a 10% random
sample of patients. All documented data were also evaluated
for implausible and outlying values. Statistical analyses were
carried out using SPSS software for Windows, version 10.0
(SPSS Inc., Chicago, IL, USA). Continuous variables are pre-
sented as mean ± standard deviation or median (25–75%
interquartile range) and compared, respectively, using Stu-
dent's t-test or Mann–Whitney U-test. Categorical variables
were reported as absolute numbers (frequency percentages)
and analyzed using χ2  test (with Yates correction where
applicable).
Validation of the prognostic scores was performed using
standard tests to measure discrimination and calibration for
each of the predictive models. The area under the receiver
operating characteristic curve (AUROC) was used to evaluate
the ability of each model to discriminate between patients who
lived from those who died (discrimination) [25]. Hosmer–
Lemeshow goodness-of-fit H statistic was used to evaluate
the agreement between the observed and expected number of
patients who did or did not die in the hospital across all of the
strata of probabilities of death (calibration) [26]. A high P value
(>0.05) would indicate a good fit for the model. Calibration
curves were constructed by plotting predicted mortality rates
stratified by 10% intervals of mortality risk (x axis) against
observed mortality rates (y axis). Standardized mortality ratios
(SMRs) with 95% confidence intervals were calculated for
each model by dividing observed by predicted mortality rates.
A two-tailed P  value < 0.05 was considered statistically
significant.
Results
During the period of study 1357 adult patients were admitted
to the ICU, and of those 1257 (92.6%) met the eligibility crite-
ria. Sources of admission were distributed as follows: wards
(n = 234 [18.6%]), emergency room (n = 156 [12.4%]), oper-
ating room (n = 853 [67.9%]) and other hospital (n = 14
[1.1%]). Patients were referred from another hospital because
of a severe medical complication and had to have a prior diag-
nosis of malignancy. Based on the reason for ICU admission,
there were 404 (32.1%) medical, 715 (56.9%) scheduled sur-
gical and 138 (11.0%) emergency surgical patients. At admis-
sion and during the first day of ICU stay, 468 (37.2%) patients
required mechanical ventilation (MV), 302 (24.0%) received
therapy with vasopressors, and 64 (5.1%) received haemodi-
alysis. Within 2 hours before and the first 24 hours after ICU
admission, 39 (3.1%) patients presented with cardiac arrest
and 362 (28.8%) patients had a definite or probable diagnosis
of infection. Median (25–75% interquartile range) lead time
was 2 (1–5) days, hospital stay was 12 (8–25) days and ICU
stay was 2 (1–6) days. The patients' demographical and clini-
cal characteristics are shown in Table 1 and their cancer
related data are summarized in Table 2. Global hospital mor-
tality was 28.6% (360/1257) and the global ICU mortality rate
was 20.8% (261/1257). As expected, hospital mortality was
significantly higher for medical (69.4%) and emergency surgi-
cal patients (49.3%) than for scheduled surgical ones (5.7%;
P < 0.001).
The performance of each individual mortality prediction system
among all patients is presented in Table 3. All models exhib-
ited excellent discriminatory power but calibration was poor.
General prognostic scores underestimated the observed mor-
tality (SMR > 1). By contrast, the CMM tended to overestimate
(SMR = 0.51, 95% confidence interval 0.46–0.57).Critical Care    August 2004  Vol 8 No 4    Soares et al.
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To better compare the performances of the CMM and of the
general prognostic scores, all scheduled surgical patients
were excluded, and therefore 542 (43.1%) patients were
included in this analysis. A total of 411 (75.8%) patients had
solid tumours and 131 (24.2%) had haematological malignan-
cies. Their mean age was 58.7 ± 16.7 years and their mean
Sequential Organ Failure Assessment score was 7.6 ± 4.2
points. Out of these patients, 380 (70.1%) had acute respira-
tory failure. Hospital and ICU mortality rates were 58.7% (318/
Table 1
Patients' demographical and clinical characteristics (n = 1257)
Parameter Value
Age (years) 56.0 ± 16.7 (18–93)
Male sex 660 (52.5%)
SOFA (points) 3 (2–7, 1–19)
APACHE II (points) 12 (8–18, 0–48)
APACHE III-J® (points) 44 (27–71, 3–199)
SAPS II (points) 29 (18–47, 0–121)
Primary reason for ICU admission
Scheduled surgical patients 715 (56.9%)
Craniotomy 281 (22.3%)
Gastrointestinal surgery 146 (11.6%)
Head and neck surgery 116 (9.2%)
Lung resection 101 (8.0%)
Genitourinary surgery 41 (3.3%)
Other 30 (2.4%)
Emergency surgical patients 138 (11.0%)
Complications of previous GI surgery 72 (5.7%)
GI perforation/rupture 12 (1.0%)
GI obstruction 12 (1.0%)
Intracranial haemorrhage 8 (0.6%)
Cholangitis/cholecystectomy 7 (0.6%)
Other 27 (2.1%)









Cardiopulmonary arrest 19 (1.5%)
Metabolic disturbances 15 (1.2%)




Status epilepticus 12 (1.0%)
GI bleeding 10 (0.8%)
Other 26 (2.1%)
A total of 1257 patients were included. Values are expressed as 
mean ± standard deviation (range); median (interquartile range, 
range); or n (%). APACHE, Acute Physiology and Chronic Health 
Evaluation; GI, gastrointestinal; ICU, intensive care unit; SAPS, 






Solid tumour 1116 (88.8%)
Brain tumour 286 (22.8%)
Gastrointestinal cancer 282 (22.4%)
Head and neck cancer 189 (15.0%)
Lung cancer 129 (10.3%)
Urogenital cancer 83 (6.6%)
Breast cancer 58 (4.6%)
Other 89 (7.1%)
Haematological 141 (11.2%)
Non-Hodgkin's lymphoma 75 (6.0%)
Hodgkin's disease 13 (1.0%)
Leukaemia 28 (2.2%)
Multiple myeloma 22 (1.8%)
Other 5 (0.4%)











Treatments prior to ICU admission (past 6 months)
Chemotherapy 273 (21.7%)
Radiation therapy 314 (25.0%)
Surgery 814 (64.8%)
A total of 1257 patients were included. ICU, intensive care unit.Available online http://ccforum.com/content/8/4/R194
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542) and 43.9% (238/542), respectively. The ICU (47.8%
versus 32.6%; P = 0.003) and hospital (61.9% versus 49.3%;
P = 0.013) mortality rates for medical patients were signifi-
cantly greater than for emergency surgical patients. Patients
with haematological malignancies had higher mortality than
did those with solid tumours (67.2% versus 56.0%; P  =
0.030). Their median scores were 18 (25–75% interquartile
range 13–25, range 4–48) for APACHE II, 74 (55–99, range
7–199) for APACHE III-J and 50 (37–64, range 6–121) for
SAPS II. Results for the performance of the six prognostic
scores are shown in Table 4. As was observed for all patients
combined, among medical and emergency surgical patients
SAPS II exhibited the best discriminative ability (AUROC =
0.815) and MPM II0 the poorest (AUROC = 0.729), and all of
the scores were poorly calibrated. Statistically significant dif-
ferences between observed and predicted mortality rates,
using goodness-of-fit H statistics, were obeserved for all
scores. Significant underestimation of actual mortality by gen-
eral scores and overestimation by the CMM were again
observed. The impacts of the differences between actual and
predicted mortality rates are demonstrated in the calibration
curves (Figs 1 and 2).
Discussion
Many severity-of-illness scores have been developed and used
to predict outcome in critically ill patients. During the past few
years a series of studies dealing with the application of out-
come prediction models in general critically ill patients demon-
strated a similar pattern – good discrimination with poor
calibration. This pattern has been observed in different set-
tings and with different instruments [27]. Information regard-
ing the usefulness of these general scores in cancer patients
Table 3
Performance of each mortality prediction system for all patients
Prognostic score ROC curve Goodness-of-fit H-test Predicted mortality (mean ± SD) SMR (CI 95%)
AUROC ± SE 95% CI χ2 P
SAPS II 0.916 ± 0.009 0.899–0.933 29.400 <0.001 24.4 ± 29.2 1.17 (1.03–1.34)
APACHE III 0.915 ± 0.009 0.898–0.933 117.206 <0.001 20.3 ± 28.2 1.41 (1.23–1.62)
MPM II24 0.909 ± 0.009 0.891–0.926 114.713 <0.001 19.1 ± 23.4 1.50 (1.30–1.73)
CMM 0.892 ± 0.011 0.871–0.913 517.662 <0.001 55.9 ± 27.5 0.51 (0.46–0.57)
APACHE II 0.888 ± 0.010 0.868–0.907 78.181 <0.001 20.4 ± 23.0 1.41 (1.22–1.62)
MPM II0 0.854 ± 0.012 0.830–0.878 373.317 <0.001 13.5 ± 18.7 2.12 (1.80–2.50)
Shown are area under receiver operating curves (AUROCs), Hosmer–Lemeshow goodness-of-fit H statistics, and standardized mortality ratios 
(SMRs) for individual mortality prediction models (degrees of freedom = 8). A total of 1257 patients were included. The observed hospital 
mortality was 28.6%. APACHE, Acute Physiology and Chronic Health Evaluation; AUROC, area under receiver operating characteristic curve; CI, 
confidence interval; CMM, Cancer Mortality Model; MPM, Mortality Probability Model; SAPS, Simplified Acute Physiology Score; SD, standard 
deviation; SE, standard error; SMR, standardized mortality rate.
Table 4
Performance of each mortality prediction system for medical and emergency surgical patients (excluding scheduled surgical 
patients)
Prognostic score ROC curve Goodness-of-fit H-test Predicted mortality (mean ± SD) SMR (95% CI)
AUROC ± SE 95% CI 95% χ2 P
SAPS II 0.815 ± 0.018 0.780–0.851 49.315 <0.001 47.9 ± 29.9 1.23 (1.09–1.37)
APACHE III 0.812 ± 0.018 0.776–0.847 113.113 <0.001 42.6 ± 30.2 1.38 (1.22–1.55)
CMM 0.795 ± 0.019 0.758–0.833 150.411 <0.001 78.7 ± 20.7 0.75 (0.69–0.81)
MPM II24 0.792 ± 0.019 0.754–0.830 124.237 <0.001 37.7 ± 24.9 1.56 (1.37–1.77)
APACHE II 0.754 ± 0.021 0.713–0.794 129.729 <0.001 38.2 ± 24.1 1.54 (1.35–1.75)
MPM II0 0.729 ± 0.022 0.686–0.771 645.464 <0.001 25.0 ± 23.0 2.35 (2.00–2.77)
Shown are areas under receiver operating curve (AUROCs), Hosmer–Lemeshow goodness-of-fit H statistics, and standardized mortality ratios 
(SMRs) for individual mortality prediction models (degrees of freedom = 8). A total of 542 patients were included. The observed hospital mortality 
was 58.7%. APACHE, Acute Physiology and Chronic Health Evaluation; CI, confidence interval; CMM, Cancer Mortality Model; MPM, Mortality 
Probability Model; SAPS, Simplified Acute Physiology Score; SD, standard deviation; SE, standard error; SMR, standardized mortality rate.Critical Care    August 2004  Vol 8 No 4    Soares et al.
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requiring ICU care is still restricted and most reports are lim-
ited by relatively small sample sizes and/or the statistical anal-
yses used in the assessment of models' performance [28-32].
In order to better address these issues, we conducted the
present study to evaluate simultaneously the performance of
five general prognostic scores and to validate the CMM in a
large prospective cohort of cancer patients requiring ICU
admission. The hospital mortality (28.6%) for the group of ICU
cancer patients evaluated here seems to be low at a first
glance. However, two thirds of our patients were admitted for
routine postoperative care following elective surgery. When
these patients were excluded, the hospital mortality (58.7%)
was similar to that in previous studies dealing with large
cohorts of critically ill cancer patients (33–58.7%) [8-
11,16,17]. Staudinger and coworkers [5] reported that ICU
mortality was 47% and 1-year mortality was 77%. Mortality
may vary with respect to the mix of patients (e.g. type of
tumour, number of BMT patients, disease status and extent,
and level of ICU support). In particular, the prognosis for can-
cer patients receiving MV is very poor. In a large prospective
study conducted in 782 patients requiring MV, 76% died in
the hospital [33]. In the present cohort about 37% of patients
received MV.
Whether studying the entire population or the subgroup of
nonscheduled surgical patients, all of the general models
tested in the present study had comparatively similar levels of
performance. As expected, they significantly underestimated
the mortality rate. In general, discrimination was satisfactory
(especially for the SAPS II and the APACHE III-J scores), but
calibration was inadequate. Studying all patients, AUROC val-
ues were remarkably high (>0.850). The higher proportion of
Figure 1
Calibration curves for the six severity-of-illness scores (solid lines) for all 1257 patients Calibration curves for the six severity-of-illness scores (solid lines) for all 1257 patients. The diagonal dotted line represents the line of ideal predic-
tion. Columns represent the number of patients in each stratum (10% of probability). APACHE, Acute Physiology and Chronic Health Evaluation; 
CMM, Cancer Mortality Model; MPM, Mortality Probability Model; SAPS, Simplified Acute Physiology Score.Available online http://ccforum.com/content/8/4/R194
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scheduled surgical patients (very low mortality), in contrast to
patients with a severe illness (whether medical or emergency
surgical), could be responsible for this finding. When those
patients were excluded, AUROC values were similar to those
reported in the literature [4,9,15-17]. To our knowledge, there
is no conventional method for comparing goodness-of-fit χ2
tests, but it seems that this statistic was considerably lower for
the SAPS II score than for the other models. This can be better
appreciated in the calibration curves, which indicate signifi-
cant underestimates in practically all of the strata of predicted
mortality. Nevertheless, the line of observed mortality for the
SAPS II score was closer to the line of equality when com-
pared with other general scores. Assessments of both calibra-
tion and discriminatory abilities of general prognostic scores in
cancer patients were reported in recent years, and yielded
conflicting results [4,9,15-17]. These scores usually tend to
underestimate the observed mortality [9,15,16,34]. Groeger
and coworkers [9] tested the MPM II0 model in the first 805
patients included in the sample from which the CMM was
developed. The MPM II0 model exhibited both poor calibration
and poor discrimination, and underestimated the mortality.
Sculier and coworkers [16] reported similar findings from their
evaluation of the APACHE II and the SAPS II scores in a
cohort of 261 patients. Guiguet and coworkers [15], studying
98 neutropenic cancer patients, found a reasonable discrimi-
nation (AUROC = 0.78) and good calibration for SAPS II. In a
retrospective study conducted in 124 patients with haemato-
logical cancer, Benoit and colleagues [4] recently reported
similar results for the SAPS II (AUROC = 0.765) and the
APACHE II (AUROC = 0.712) scores. However, the results of
Figure 2
Calibration curves for the six severity-of-illness scores (solid lines) for the sample (excluding scheduled surgical patients; n = 542) Calibration curves for the six severity-of-illness scores (solid lines) for the sample (excluding scheduled surgical patients; n = 542). The diagonal dot-
ted line represents the line of ideal prediction. Columns represent the number of patients in each stratum (10% of probability). APACHE, Acute 
Physiology and Chronic Health Evaluation; CMM, Cancer Mortality Model; MPM, Mortality Probability Model; SAPS, Simplified Acute Physiology 
Score.Critical Care    August 2004  Vol 8 No 4    Soares et al.
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calibration analyses in the latter two studies should be inter-
preted with caution because of the relatively small numbers of
patients included, so that differences between predicted and
observed mortalities may not reach statistical significance. In
an elegant study, Zhu and coworkers [14] analyzed the impact
of sample size on the accuracy of MPM II models by perform-
ing computer simulations. They showed that the smaller the
sample size, the better the model calibration, as demonstrated
by lower values of the goodness-of-fit χ2 statistics. In contrast,
discrimination was not affected by sample size.
The limitations of general prognostic models in predicting out-
come in cancer patients motivated investigators to develop a
specific model. Reported in 1998, the CMM was developed in
a multicentre study from a cohort of 1483 critically ill cancer
patients to predict hospital mortality at admission to the ICU,
and it was further validated in another 230 patients [9]. By
containing variables specific to oncology (disease progres-
sion/recurrence, performance status and allogeneic BMT
group), this model was expected to be a more accurate scor-
ing system in cancer patients [5,16]. SAPS II, APACHE II,
APACHE III-J and MPM II24 models also take into account the
presence of some cancer diagnostic categories, but they were
not derived exclusively from cancer patients. The performance
of the CMM was studied in medical and emergency surgical
patients separately (i.e. excluding elective surgical patients) in
order to minimize selection bias. There was no mention in the
intial CMM report that elective surgical patients had been
included in its development. At our ICU, CMM exhibited good
discrimination and the AUROC value (0.795) is similar to val-
ues observed in both generation (0.812) and validation
(0.802) groups of patients. However, CMM was poorly
calibrated and, in contrast to general scores, exhibited a ten-
dency to overestimate the observed mortality. Recently, Schel-
longowski and coworkers [17] compared the levels of
performance of CMM, SAPS II and APACHE II in 242 ICU
cancer patients [17]. In that study, the ability of SAPS II to dis-
criminate between survivors and nonsurvivors (AUROC =
0.825) was superior to those of APACHE II (AUROC = 0.776)
and CMM (AUROC = 0.698). All scores had acceptable cali-
bration, although the statistical significance for the Hosmer–
Lemeshow goodness-of-fit tests was borderline. The authors
emphasized the limitations imposed by relatively small sample
size on the results of calibration analyses.
The present study also has potential limitations. Ideally, a prog-
nostic score should be employed in populations with similar
characteristics to the sample of patients in which it was devel-
oped. Because we did not study BMT patients, it can be
argued that our patients were less severely ill than those stud-
ied by Groeger and coworkers [9]. In that study, 11.3% and
5.8% of the sample were allogeneic and autologous BMT
patients, respectively. These patients are considered to have
the worst prognosis among cancer patients requiring intensive
care, and prognosis is particularly poor when such patients
need MV [16,35,36]. Our patients (excluding elective surgical
patients) actually had a higher hospital mortality rate (58.7%
versus 42%), but it was not feasible to make reliable compari-
sons of acute physiological disturbances (e.g. organ failures)
between groups. In addition, whenever case mix adjustments
are attempted, possible selection bias – resulting from
different approaches to care (e.g. do-not-resuscitate orders)
and from ICU admission/discharge policies – cannot be ruled
out, especially in a single centre. Decisions to forgo life-sus-
taining therapy were demonstrated to independently predict
hospital death in ICU patients [37]. Our ICU policies, including
decisions to offer end-of-life care, appear similar to those
reported in the literature [16,17].
Another issue that deserves mention is the impact of missing
data on the performance of models; in the present study pro-
thrombin time, and serum albumin and bilirubin were not
obtained in all patients. The differences between the predicted
mortality with each score and the observed mortality were con-
siderable, but there is a possible impact of missing data in the
unsatisfactory performance of the models. As stated above,
the study did not interfere with clinical decisions, including
request for laboratory tests. In particular, the poor perform-
ance of the CMM cannot be attributed to missing data
because it significantly overestimated the mortality rate.
Finally, we should be cautious when using SMR findings to
evaluate the quality of intensive care. The prognostic scores
that are already available do not take into consideration multi-
dimensional parameters (ICU organizational and economic
aspects in addition to clinical variables) in evaluating ICU per-
formance [38].
In conclusion, none of the severity-of-illness scores evaluated
in the present study were accurate in predicting outcome for
critically ill cancer patients. Moreover, similar to a recent report
[17], we found no advantage of CMM over the general prog-
nostic models. It must be re-emphasized that any prognostic
model should not be the only parameter taken into account
when predicting outcome, and neither should they be used for
triage and cost containment in individual patients. After all,
prognostic scores were constructed based on patients who
have been effectively admitted to the ICU. Otherwise, an accu-
rate score may be helpful in enroling patients in clinical trials
and enriching discussions about prognosis in intensive care.
Key messages
None of the severity-of-illness scores evaluated in the 
present study were accurate in predicting outcome for 
critically ill cancer patients. There was no advantage of 
CMM over the general prognostic models. Prognostic 
scores should not be the only parameters taken into 
account when predicting outcome, and neither should 
they be used for triage and cost containment in individ-
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